Neumora Therapeutics Files 8-K/A Amendment
Ticker: NMRA · Form: 8-K/A · Filed: Feb 21, 2025 · CIK: 1885522
| Field | Detail |
|---|---|
| Company | Neumora Therapeutics, INC. (NMRA) |
| Form Type | 8-K/A |
| Filed Date | Feb 21, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, amendment, officer-changes
TL;DR
Neumora filed an 8-K/A amendment regarding director/officer changes and compensation.
AI Summary
Neumora Therapeutics, Inc. filed an amendment (8-K/A) on February 21, 2025, to its previous filing. This amendment pertains to the departure of directors or certain officers, the election of directors, and the appointment of certain officers, as well as compensatory arrangements for certain officers. The earliest event reported in this amendment was on February 13, 2025.
Why It Matters
This filing indicates changes in the company's board of directors and executive team, which could signal shifts in strategy or governance.
Risk Assessment
Risk Level: low — The filing is an amendment to a previous report and concerns routine corporate governance matters.
Key Numbers
- 001-41802 — SEC File Number (Identifies the company's filing history with the SEC)
- 84-4367680 — IRS Employer Identification Number (Tax identification number for the company)
Key Players & Entities
- Neumora Therapeutics, Inc. (company) — Registrant
- February 13, 2025 (date) — Earliest event reported
- February 21, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Watertown, Massachusetts (location) — Principal executive offices
FAQ
What specific changes are being reported regarding directors or officers?
The filing is an amendment to report on the departure of directors or certain officers, election of directors, and appointment of certain officers.
What is the date of the earliest event reported in this amendment?
The earliest event reported was on February 13, 2025.
What is the filing date of this 8-K/A amendment?
The filing was made as of February 21, 2025.
What is the company's state of incorporation?
The company is incorporated in Delaware.
What are the company's principal executive offices?
The principal executive offices are located at 490 Arsenal Way, Suite 200, Watertown, Massachusetts 02472.
Filing Details
This Form 8-K/A (Form 8-K/A) was filed with the SEC on February 21, 2025 regarding Neumora Therapeutics, Inc. (NMRA).